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Abstract
Glutathione (GSH), a tripeptide antioxidant, is essential for cellular homeostasis and plays a vital role in diverse cellular
functions. Individuals who are infected with Human immuno deficiency virus (HIV) are known to be susceptible to
Mycobacterium tuberculosis (M. tb) infection. We report that by enhancing GSH levels, T-cells are able to inhibit the growth of
M. tb inside macrophages. In addition, those GSH-replenished T cell cultures produced increased levels of Interleukin-2 (IL-
2), Interleukin-12 (IL-12), and Interferon-gamma (IFN-c), cytokines, which are known to be crucial for the control of
intracellular pathogens. Our study reveals that T lymphocytes that are derived from HIV infected individuals are deficient in
GSH, and that this deficiency correlates with decreased levels of Th1 cytokines and enhanced growth of M. tb inside human
macrophages.
Citation: Guerra C, Morris D, Sipin A, Kung S, Franklin M, et al. (2011) Glutathione and Adaptive Immune Responses against Mycobacterium tuberculosis Infection
in Healthy and HIV Infected Individuals. PLoS ONE 6(12): e28378. doi:10.1371/journal.pone.0028378
Editor: Shabaana Khader, University of Pittsburgh, United States of America
Received June 28, 2011; Accepted November 7, 2011; Published December 2, 2011
Copyright:  2011 Guerra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by start-up funds from Western University of Health Sciences and Potts Memorial Foundation. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Although, one of the co-authors of this manuscript is a Managing Partner for Your Energy Systems (a small biotech company), this does
not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: vvenketaraman@westernu.edu
Introduction
HIV is the cause of acquired immunodeficiency syndrome
(AIDS). Both HIV-1 and HIV-2 cause AIDS, but HIV-1 is found
worldwide, whereas HIV-2 is found primarily in West Africa
[1,2,3]. Blood monocytes, CD4 T lymphocytes and resident
macrophages are important in vivo cell targets for HIV infection
and their role in AIDS pathogenesis are well documented [1,2,3-
5]. HIV preferentially infects and kills CD4+ T lymphocytes,
resulting in the loss of cell-mediated immunity and a high
probability that the host will develop opportunistic infections
including tuberculosis (TB).
M. tb is endemic in every part of the world. This organism
accounts for nearly 1.7 million deaths annually, making it the
leading bacterial cause of death worldwide [1]. Once thought to be
controlled,theincidenceofTBis rising inmanyareascausedinpart
by the emergence of drug-resistant strains and the HIV epidemic.
Furthermore, nearly one-third of the world is latently infected with
M. tb, making eradication of the organism difficult [1].
Although TB remains the leading cause of morbidity and
mortality due to any one infectious agent worldwide [6] our
understanding of its immunopathogenesis is still incomplete.
M. tb infection begins as primary TB with the deposition of
bacilli in the alveoli, which are phagocytosed by alveolar
macrophages [7]. Active TB is characterized by a profound and
prolonged suppression of M. tb-specific T cell responses, as
evidenced by decreased production of the cytokines IL-2 and IFN-
c [8-11,12]. Overproduction of immunosuppressive cytokines [IL-
10 and transforming growth factor (TGF)- b] by mononuclear
phagocytes has been implicated in decreased T cell function
during TB [8,13-15].
GSH plays a major role in the maintenance of the cellular redox
state. GSH scavenges peroxide species which can be harmful to
the cells. GSH also plays a role in the normal function of the
immune system [3]. Of particular interest, is the ability of GSH to
enhance the activation of lymphocytes which play a major role in
the pathology of HIV infection. GSH has been demonstrated to be
depleted in HIV positive individuals [3]. Low GSH levels have
been shown to result in the activation of nuclear factor kB (NFkB),
which is necessary for active transcription of the HIV provirus
[4,5,16]. Depleted GSH levels have also been shown to play a role
in the apoptosis of CD4
+ T cells. As depletion of these T cells is the
major pathology of the HIV virus, replenishment of GSH
represents an exciting prospect for treatment as a supplement to
highly active antiretroviral therapy (HAART) [17].
Our earlier studies indicated that GSH facilitates the control of
growth of intracellular M. tb in both murine and human
macrophages and has direct antimycobacterial activity [18-20].
Furthermore, our recent studies indicate that GSH in combination
with IL-2 and IL-12 augments natural killer (NK) cell functions to
control M. tb infection [21].
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control of M. tb infection as indicated by our previous studies [18-
20] led us to hypothesize that GSH will also augment the activity
of T-cells resulting in the control of M. tb infection inside
macrophages. Further, we believe that the decreased intracellular
growth of M. tb will be accompanied by increased production of
Th1 cytokines that are essential for the control of intracellular
pathogens. We tested our hypothesis by performing extensive in
vitro studies using monocytes and T cells that are isolated from
blood of healthy subjects and individuals with HIV infection. Our
results indicate that individuals with HIV infection have
significantly lower levels of GSH in their T cells in comparison
to healthy subjects. The decrease in the GSH levels correlated with
increased growth of M. tb inside human macrophages and reduced
levels of Th1 cytokines in both plasma and cell free supernatants
derived from monocyte-T cell co-cultures. Our results signify the
importance of GSH in augmenting the functions of T lymphocytes
to limit the growth of M. tb inside monocytes and macrophages.
Results
Assay of GSH levels in T cells from healthy and HIV-
infected subjects
GSH levels were determined in freshly isolated T cells from
thirteen healthy subjects and thirteen individuals with HIV
infection. We observed that GSH concentrations were significantly
lower in T cells isolated from individuals with HIV infection
compared to T cells from healthy subjects (Figure 1a). The
decreased levels of intracellular GSH in T cells from HIV-infected
individuals correlated with increased levels of TNF-a and free
radicals. Decreased GSH levels in T cells of HIV positive
individuals are likely to impair the adaptive immune responses
against M. tb infection. NAC-treatment of T cells from individuals
with HIV infection resulted in significant increase in the levels of
GSH (Figure 1b). Treatment of T cells from HIV positive
individuals with BSO resulted in significant decrease in the levels
of GSH (Figure 1b).
Assay of free radicals and TNF-a in plasma samples
MDA is a naturally formed byproduct of the interaction
between free radicals and lipid molecules which occurs in the
body. The interaction between free radicals and lipid molecules
produces lipid peroxides which are unstable and decay to MDA
and other products. Concentrations of MDA are indicative of
the level of cellular damage due to free radicals and therefore
are also indicative of levels of free radicals. Measurement of
MDA concentrations in the plasma of thirteen healthy and
thirteen HIV infected individuals revealed a significant increase
in the amounts of MDA present in the plasma of HIV infected
individuals over those found in healthy individuals (Figure 2a).
We observed an eight-fold increase in the levels of TNF-a in the
plasma samples of HIV infected individuals compared to
healthy subjects (Figure 2b). Thed i f f e r e n c ei np l a s m al e v e l so f
TNF-a did not reach statistical significance due to a high
variance in the TNF-a concentrations measured in HIV
infected individuals.
Figure 1. Assay of GSH levels in T cells isolated from healthy and HIV positive individuals. Intracellular levels of GSH in freshly isolated T
cells from healthy volunteers and HIV-infected individuals was determined by spectrophotometry, using an assay kit from Calbiochem (Figure 1a). T
cells (2610
5/well) purified from PBMCs using nylon wool columns were pelleted by centrifugation and an equal volume of ice cold 5% MPA was
added to the pellet. Supernatants were collected after centrifugation and analyzed for total GSH using an assay kit from Calbiochem, as per
manufacturer’s instructions. Total GSH in the samples were normalized with protein. Proteins in the samples were estimated by Bradford’s method
using Bio-Rad reagent. We also tested the effects of NAC and BSO in increasing and decreasing the intracellular levels of GSH, respectively in T cells
isolated from both healthy subjects and individuals with HIV infection (Figure 1b). T cells (2610
5/well) isolated from healthy and HIV positive subjects
were treated as follows: mock treatment, treatment with NAC (10 mM) and treatment with BSO (500 mM). Following overnight incubation, T cells
were pelleted and used for GSH measurement as per manufacturer’s instructions. Results shown in Figure 1b are averages from experiments
performed using T cells isolated from three healthy individuals and eight individuals with HIV infection. * represent significant difference in the levels
of GSH between untreated T cells derived from healthy subjects versus untreated T cells derived from individuals with HIV infection. **denotes
significant difference in the levels of GSH between untreated T cells versus NAC-treated T cells from HIV positive subjects. *** denotes statistically
significant difference in the levels of GSH between NAC-treated T cells and BSO-treated T cells from individuals with HIV infection.
doi:10.1371/journal.pone.0028378.g001
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monocyte-T cell co-cultures from healthy and HIV
positive individuals
We then tested the intracellular survival of M. tb in co-cultures
of monocytes and T cells that were isolated from healthy subjects
and individuals with HIV infection. Results from the six healthy
subjects revealed a two-fold increase in the growth of M. tb inside
monocytes cultured both in the presence and absence of T cells
(Figure 3a). Incubation with NAC (10 mM)-treated T cells resulted
in stasis in the growth of M. tb inside monocytes (Figure 3a).
Incubation with BSO-treated T cells resulted in abrogation in the
growth inhibition and a six-fold growth of M. tb inside monocytes
confirming that GSH enhances the functions of T lymphocytes to
control M. tb infection inside monocytes (Figure 3a). Whereas in
HIV positive individuals, we observed a six-fold increase in the
growth of M. tb inside monocytes cultured in the absence of T cells
(Figure 3b) and five-fold increase in the growth of M. tb in
monocytes cultured in the presence of mock-treated T cells
(Figure 3b). These results indicate that monocytes and T cells from
HIV positive individuals are unable to restrict the growth of M. tb
to the same extent as healthy individuals. Treatment of T cells
from HIV positive subjects with 10 mM NAC and co-incubation
with infected monocytes resulted in reduction in the fold increase
in growth of M. tb inside monocytes compared to other treatment
Figure 2. Assay of free radicals and TNF-a in plasma samples from healthy and HIV positive individuals. Plasma samples separated from
blood of healthy volunteers and HIV-infected individuals were used for measurement of free radicals (Figure 2a) and TNF-a (Figure 2b). Free radical
levels in plasma samples derived from healthy subjects and individuals with HIV infection was determined by measuring the levels of MDA using a
colorimetric assay kit from Cayman. Levels of TNF-a in the plasma samples were determined by ELISA using assay kits procured from eBioscience.
Results in Figure 2 are averages of data collected from thirteen healthy subjects and thirteen individuals with HIV infection.
doi:10.1371/journal.pone.0028378.g002
Figure 3. Intracellular survival of H37Rv inside T cell-monocyte co-cultures. We determined the intracellular survival of H37Rv inside T cell-
monocyte co-cultures from healthy subjects (Figure 3a) and individuals with HIV infection (Figure 3b). Human monocytes were infected with the
processed virulent laboratory strain of M. tb, H37Rv at a multiplicity of infection of 10:1. T cells were purified using nylon wool column. T cells were
treated as follows: a) no additives b) NAC (5 mM) c) NAC (10 mM) d) NAC (20 mM) and e) BSO (500 mM) for 24 h. T cells were washed, resuspended in
fresh media and then added to the infected monocytes. Infected monocytes-T cell co-cultures were terminated at 1 hour and 5 days post-infection to
determine the intracellular survival of H37Rv inside human monocytes. Monocyte lysates were plated on 7H11 medium enriched with ADC to
estimate the growth or killing of H37Rv. Results shown in Figure 3a are averages from five different experiments performed in triplicate. Results
shown in Figure 3b are averages from seven different experiments performed in triplicate.
doi:10.1371/journal.pone.0028378.g003
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result in complete stasis in the growth of M. tb as seen in healthy
subjects (Figure 3b). We also observed a poor uptake of M. tb by
monocytes derived from individuals with HIV infection compared
to healthy individuals as evidence by lower colony counts
recovered from the co-cultures of monocytes and T cells
(Figure 3b). This reduced uptake of M. tb could possibly be due
to impaired phagocytic capacity of monocytes that are derived
from HIV positive individuals.
Assay of IL-12, IL-2 and IFN-c in supernatants derived
from T cell-monocyte co-cultures
To determine whether the growth inhibition of M. tb in
monocyte-T cell co-cultures is accompanied by increased
production of IL-12, IL-2 and IFN-c, we quantified the levels of
these cytokines in the cell free-supernatants from co-cultures of M.
tb-infected monocytes and T cells (from healthy subjects and
individuals with HIV infection) by ELISA (Figure 4). We observed
an increase in the production of IL-12, IL-2 and IFN-c in
monocyte+NAC-treated T cell co-cultures derived from healthy
subjects (Figure 4a, b and c). These results indicate that increasing
GSH in T cells favors the synthesis of Th-1 cytokines leading to
the control of Mt binfection. We also quantified the levels of IL-12,
IL-2 and IFN-c in monocyte-T cell co-cultures from individuals
with HIV infection (Figure 4d and e). We were unable to detect
IL-12 in the culture supernatants. IL-2 and IFN-c were detected in
monocyte-T cell co-cultures however the levels of these cytokines
were almost one log lower compared to the healthy individuals
(Figure 4d and e). This signifies the consequences of HIV infection
on T cell functions. Since mycobacteria are not internalized by T
cells the downregulation in the production of IFN-c and IL-2 by T
cells is an HIV induced effect.
Assay of IL-12, IL-2, IFN-c and IL-10 levels in plasma
samples from healthy and HIV-infected subjects
Measurement of Th-1 cytokines such as IL-12, IL-2 and IFN-c
in plasma samples from thirteen healthy and thirteen HIV infected
individuals revealed a significant reduction in the levels of these
Figure 4. Assay of IL-12, IL-2 and IFN-c in supernatants derived from co-cultures of T cells-M. tb-infected monocytes. Levels of IL-12,
IL-2 and IFN-c were assayed in supernatants derived from co-cultures of T cells-M. tb-infected monocytes from healthy individuals (Figure 4a, b and c)
and individuals with HIV infection (Figure 4d and e) T cells were purified using nylon wool column. T cells were treated as follows: 1) no additives 2)
NAC (5 mM) 3) NAC (10 mM) 4) NAC (20 mM) and 5) BSO (500 mM) for 24 h. Following incubation with stimulants, T cells were washed, re-suspended
in fresh RPMI containing human serum without any stimulants and then added to the infected monocytes. Supernatants were collected from co-
cultures of H37Rv-infected monocytes-T cells at 5 days post-infection were filtered and assayed for the levels of IL-12, IL-2 and IFN-c using assay kits
from eBioscience. Data in Figures 4a, b and c represent means6SE from four different healthy individuals. Data in Figures 4d and e represent
means6SE from six different individuals with HIV infection.
doi:10.1371/journal.pone.0028378.g004
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subjects. We observed a statistically significant (i.e., 50%) decrease
in the levels of IL-12 in plasma samples from individuals with HIV
infection compared to healthy subjects (Figure 5a). Decreased
levels of IL-12 will interfere with the differentiation of Th0 to Th1
subset [22]. We also observed a 20% decrease in the levels of IL-2
in plasma samples derived from individuals with HIV infection
compared to healthy subjects (Figure 5b).Decreased levels of IL-2
will interfere with the amplification of T cell responses [9].
Furthermore, we observed a significant decrease in the levels of
IFN-c in plasma samples from individuals with HIV infection
compared to healthy subjects (Figure 5c). Low levels of IFN-c will
result in enhanced susceptibility to intracellular infections [10].
Importantly, we observed a five-fold increase in the levels of IL-10
in the plasma samples derived from individuals with HIV infection
compared to healthy subjects (Figure 5d). However this increase is
not statistically significant. Increased IL-10 may promote viral
replication by inhibiting effector immune response from both arms
of the innate and adaptive immunity [14].
Discussion
Blood monocytes and resident macrophages are important in
vivo cell targets for HIV infection and their role in AIDS
pathogenesis is well documented [2]. These cells of innate immune
defenses usually survive HIV infection, serve as a major virus
reservoir, and function as immunoregulatory cells through
secretion of several pro-inflammatory cytokines and chemokines
in response to HIV infection, thereby recruiting and activating
CD4+ T cells which serve as new target cells for the virus [3-5].
GSH is the primary antioxidant compound employed by
human cells in the maintenance of the cellular redox balance.
GSH is a tripeptide made of glutamine, cysteine, and glycine and
has been shown to be important for normal function of the
immune system. In particular, we have previously demonstrated
that GSH is important for the control of intracellular M. tb
infection by the cells of the immune system [18-21]. Conditions of
depleted GSH have been demonstrated to activate transcription
factors that are necessary for active replication of the HIV within
lymphocytes [3-5, 16 &17].
In this study, we observed that GSH levels are compromised in
T lymphocytes derived from individuals with HIV infection
(Figure 1) and this decrease correlated with increased levels of
TNF-a and free radicals in the plasma compared to healthy
subjects (Figure 2).
TNF-a, a pro-inflammatory cytokine is considered to play a
critical role in the origin and progression of HIV infection [23].
The immuno-regulatory response of the host influences the
pathogenesis of HIV-1 infection, triggering monocytes, macro-
phages, and natural killer cells to produce TNF-a [24]. As a result,
there is a positive correlation between HIV-1 viremia and TNF-a
levels in serum of HIV-1 infected patients. This relationship
suggests that reducing TNF-a levels may also reduce occurrence of
HIV-1 viremia. In excess, TNF-a may cause severe inflammatory
damage and toxicity, making control of its production and
secretion highly important. Regulating its release serves as a
potential means of therapy for HIV-1. TNF-a can also induce
other pro-inflammatory cytokines such as IL-6 and IL-8, which aid
in the upregulation of viral replication [25]. Studies have also
shown the ability of TNF-a to stimulate production of anti-
Figure 5. Assay of IL-12, IL-2, IFN-c and IL-10 in plasma samples from healthy and HIV positive individuals. Plasma samples separated
from blood of healthy volunteers and HIV-infected individuals were used for measurement of IL-12 (Figure 5a), IL-2 (Figure 5b), IFN-c (Figure 5c) and
IL-10 (Figure 5d) by ELISA using assay kits from eBioscience. Results in Figure 5 are averages from data collected from thirteen healthy subjects and
thirteen individuals with HIV infection.
doi:10.1371/journal.pone.0028378.g005
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causing TNF-a inhibition [26]. TNF-a is secreted during the early
phase of acute inflammatory diseases. Its pathogenic role in HIV-1
infection involves activation of NF-kB, stimulating apoptosis of T
lymphocytes. Tissue and plasma samples of hosts express high
levels of TNF-a, contributing to fever, anorexia, and other
symptoms of HIV/AIDS.
It has been shown that HIV infection results in increased
production of free radicals and TNF-a by macrophages [23,24].
TNF-a stimulates the production of free radicals. Moreover,
enhanced levels of free radicals are likely to increase TNF-a in
various cells.
Chronic oxidative stress is often associated with HIV infection
and research indicates a benefit for increased antioxidant vitamins
and supplements in reduction of DNA base damage, which in turn
can slow progression of infection [27]. The progression of HIV is
correlated with a decreased immunity. One way in which this
decreased immunity progresses is by free radical overload of
monocytes and granulocytes leads to deficiency of antioxidant
mechanisms which, in turn, may lead to the loss of CD4 cells often
seen in the progression of HIV [28]. The decreased immunity may
also be related to the reactive oxygen species and free radical
presence which is higher in HIV infected patients. With HIV
infection progression there is an increased production of reactive
oxygen species which leads to the theory of free radical mediated
apoptosis of lymphocytes which reduces the ability for immune
response to progressive HIV infections [28]. With regards to CD4
T cell counts the apoptosis of lymphocytes by free radicals leads to
progression of immunodeficiency and makes for a quicker
transition from HIV infection to AIDS [29]. Furthermore, there
is a link to lipid peroxidation observed in patients with HIV or
AIDS to a deficiency of antioxidants which leads to free radical
proliferation [30].
Results of the co-culture studies using monocytes and T cells
from healthy individuals indicate a complete inhibition in the
growth of M. tb when infected monocytes were co-incubated with
10 mM NAC-treated T-cells (Figure 3a). Furthermore, co-
incubation of infected monocytes with BSO-treated T cells
demonstrated six-fold increase in the intracellular growth of M.
tb (Figure 3a). In contrast to healthy subjects, we observed a
several-fold increase in the growth of M. tb in co-cultures of
monocytes and T cells derived from individuals with HIV
infection (Figure 3b). Treatment of T cells derived from HIV
positive individuals with 10 mM NAC resulted in reduction in the
fold increase in growth of M. tb inside monocytes compared to
other treatment conditions but did not result in complete stasis in
the growth of M. tb as seen in healthy subjects (Figure 3b). This is
the first study to demonstrate that treatment with a GSH-
enhancing agent increases the functional activity of human T-cells
resulting in the control of M. tb infection. Our results indicate that
treatment of T cells from healthy subjects with NAC leads to the
increased production of IL-12, IL-2 and IFN-c (Figure 4a). These
cytokines drive the Th1 response and are crucially important for
the control of intracellular pathogens like M. tb.
In our study, we also observed decreased levels of IL-12, IL-2
and IFN-c in plasma samples from individuals with HIV infection
compared to healthy subjects (Figure 5a, 5b and 5c). Activated
antigen presenting cells secrete IL-12 which causes Th cell
differentiation into the Th1 subset of cells [22]. These Th1 cells
then secrete a characteristic Th1 profile of cytokines consisting of
IL-2 and IFN-c. IL-2 induces proliferation of naı ¨ve Th cells (Th0),
amplifying the Th response. IFN-c induces further IL-12
production in activated antigen presenting cells, amplifying the
Th1 response, and suppressing any Th2 response [10]. IFN-c also
plays an important role in the activation of innate immune cells
such as macrophages to control intracellular infections [10,31].
Our results are consistent with other published reports that in
individuals infected with HIV, the normal Th1 response to viral
infection is shifted to a Th2 response [31,32].
We also observed increased levels of IL-10 in plasma samples
from individuals with HIV infection compared to healthy subjects
(Figure 5d). IL-10 inhibits T cell proliferation and IFN-c
production. Elevated levels of IL-10 in serum during advanced
HIV infection may enhance immune suppression, allowing for
opportunistic infections.
Programmed death-1 (PD-1) and IL-10 are both upregulated
during HIV infection. Blocking interactions between PD-1 and
programmed death ligand-1 (PD-L1) and between IL-10 and IL-
10 receptor (IL-10R) results in viral clearance and improves T cell
function in animal models of chronic viral infections [33].
Additionally, blockade of the IL-10 pathway augmented in vitro
proliferative capacity of HIV-specific CD4 and CD8 T cells in
individuals with HIV. IL-10 blockade also increased cytokine
secretion by HIV-specific CD4 T cells [34]. Our results therefore
confirm the previous findings of other investigators that the levels
of IL-12, IL-2 and IFN-c are decreased in the plasma samples of
individuals with HIV infection (who in turn have higher IL-10)
[32-34].
Further, our results show that individuals infected with HIV
have significantly lower levels of GSH within their T cells in
comparison to healthy subjects and this decrease correlated with
reduced production of Th1 cytokines and compromised control of
M. tb infection (Figure 1, 3, 4 and 5).
To conclude, our results indicate that HIV enhances the
synthesis of TNF-a and free radicals leading to decreased levels of
GSH in T lymphocytes. The decreased GSH levels cause impaired
production of Th1 cytokines resulting in enhanced growth of M. tb
inside macrophages (Figure 6). Our findings suggest the possibility
of efficacy for supplemental GSH therapy in HIV-M. tb co-
infected individuals. In our future studies, we will further
characterize the effects of decreased GSH in altering the
functional activity of various T cell sub-populations.
Materials and Methods
Subjects
A total of 26 volunteers (13 healthy subjects and 13 individuals
with HIV infection) were recruited for the study. Individuals with
HIV infection were recruited from the Foothills AIDS project.
Healthy subjects without HIV infection or a history of TB were
recruited from the university faculty and staff. All HIV-infected
volunteers had been diagnosed with HIV-1, were taking some
form of anti-retroviral treatment (ART), and had CD4+ T-cell
counts between 271 and 1415 cells per mm
3. Thirty five milli-liters
of blood was drawn once from both healthy volunteers and
individuals with HIV infection after obtaining a signed informed
consent. All our studies were approved by both the Institutional
Review Board and the Institutional Biosafety Committee of
Western University of Health Sciences.
Separation of blood components
Blood collected from healthy and HIV-infected volunteers was
subjected to density gradient centrifugation using histopaque
(Sigma) to separate plasma, red blood cells (RBC), and peripheral
blood mononuclear cells (PBMC). PBMCs were further processed
to isolate monocytes and T cells. Plasma collected was used for
measurement of cytokines (IL-12, IL-2, IFN-c, IL-10 and TNF-a)
and free radicals.
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PBMCs isolated from the blood of healthy volunteers and
individuals with HIV infection were distributed into Poly-L-Lysine
(Sigma) coated 96-well plates (1610
5/well) and incubated
overnight at 37uC, 5% CO2, to allow monocytes to adhere.
Non-adherent cells were removed and used for isolation of T cells.
Purification of T lymphocytes
Autologous T lymphocytes were isolated from non-adherent
cells (from both healthy volunteers and individuals with HIV
infection) using nylon wool columns (Polysciences). T cells were
subjected to various treatments such as treatment with a GSH
enhancing agent, N-acetyl cysteine (NAC) and treatment with a
GSH synthesis inhibitor, buthionine sulphoximine (BSO). Specif-
ically, T cells were treated as follows: no additives, treatment with
NAC (5 mM), NAC (10 mM), NAC (20 mM), and treatment with
BSO (500 mM), for 24 h. T cells were then washed, resuspended in
fresh media containing no additives and used for various assays
such as measurement of GSH, determination of the intracellular
viability of M. tb inside monocytes and cytokine production.
Assay of GSH levels in T cells from healthy and HIV-
infected subjects
GSH levels were measured in freshly isolated T cells from
healthy subjects and individuals with HIV infection. Intracellular
levels of GSH in T cells were determined by spectrophotometry
using an assay kit from Calbiochem. Briefly, T cells (2610
5/well)
were pelleted by centrifugation and an equal volume of ice cold
5% metaphosphoric acid (MPA) was added to the pellet.
Supernatants collected after centrifugation were analyzed for total
GSH as per manufacturer’s instructions. Total GSH in the
samples was normalized with protein. Proteins in the samples were
estimated by Bradford’s method using Thermo Scientific Coo-
massie Protein Assay Reagent.
Assay of GSH levels in NAC/BSO-treated T cells from
healthy and HIV-infected subjects
We tested the effects of NAC and BSO in increasing and
decreasing the intracellular levels of GSH respectively, in T cells
isolated from both healthy subjects and individuals with HIV
infection. T cells (2610
5/well) isolated from healthy and HIV
positive subjects were treated as follows: mock treatment,
treatment with NAC (10 mM) and treatment with BSO
(500 mM). Following overnight incubation, T cells were pelleted
and used for GSH measurement as per manufacturer’s instruc-
tions.
Assay of free radicals and TNF-a in plasma samples
Free radical levels in plasma samples derived from healthy
subjects and individuals with HIV infection was determined by
measuring the levels of malondialdehyde (MDA) using a
colorimetric assay kit from Cayman. Levels of TNF-a in plasma
samples derived from healthy subjects and individuals with HIV
infection were determined by enzyme linked immuno-sorbent
assay (ELISA) using assay kits from eBioscience.
Preparation of bacterial cells for monocyte infection
All infection studies were performed using the virulent
laboratory strain of M. tb, H37Rv inside the biosafety level 3
(BSL-3) facility. M. tb was processed for infection as follows: static
cultures of H37Rv at their peak logarithmic phase of growth
(between 0.5 and 0.8 at A600) were used for infection of
monocytes. The bacterial suspension was washed and re-
suspended in RPMI (Sigma) containing AB serum (Sigma).
Bacterial clumps were disaggregated by vortexing five times with
3 mm sterile glass beads. The bacterial suspension was passed
through a 5 mm syringe filter (Millipore) to remove any further
clumps. The total number of organisms in the suspension was
ascertained by plating. Processed H37Rv was frozen as stocks at -
Figure 6. Model describing the mechanism by which GSH-enhanced T cells control M. tb infection in macrophages.
doi:10.1371/journal.pone.0028378.g006
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were thawed and used for monocyte infection.
Co-incubation of M. tb-infected monocytes with
autologous T cells
Adherent monocytes were infected with processed H37Rv at a
multiplicity of infection of 10:1 and incubated for 2 hours for
phagocytosis. Unphagocytosed mycobacteria were removed by
washing the infected monocytes three times with sterile PBS.
Infected monocytes were cultured in RPMI containing 5% AB
serum in presence and absence of autologous T cells. Prior to co-
incubation with infected-monocytes, autologous T cells were
incubated overnight with stimulants (NAC/BSO), washed with
PBS, re-suspended in fresh RPMI containing AB serum (without
any stimulants) and then added to the infected monocytes
(monocyte: T cell ratio was adjusted to 1:1). Infected monocyte-
T cell co-cultures were terminated at 1 hour and 5 days post-
infection to determine the intracellular survival of H37Rv.
Infected monocytes cultured in the absence of T cells were used
as negative controls.
Termination of infected monocytes-autologous T cell co-
cultures
M. tb-infected monocytes cultured in the presence and absence
of T lymphocytes were terminated at 1 hour and 5 days post-
infection. During termination, supernatants were removed and
adherent monocytes were lysed by addition of 200 ml sterile
distilled water. 25 ml of 10-fold diluted lysates were plated on
7H11 medium (Hi Media) enriched with albumin dextrose
complex (ADC), to estimate the extent of H37Rv growth or
killing in co-cultures of monocytes and T cells. Cell-free
supernatants were plated to determine extracellular H37Rv
growth. Cell-free supernatants were also used for determining
the levels of IL-12, IL-2 and IFN-c.
Assay of cytokines in supernatants derived from T cell-
monocyte co-cultures
Cell free-supernatants from co-cultures of M. tb-infected
monocytes and T cells (from healthy controls and individuals
with HIV infection) collected at 5 days post-infection were filtered
using 0.2 micron syringe filters (Millipore) and assayed for the
levels of IL-12, IL-2 and IFN-c. Cytokines were assayed using
ELISA kits from eBioscience.
Assay of IL-12, IL-2, IFN-c and IL-10 in plasma samples
Levels of IL-12, IL-2, IFN-c and IL-10 in plasma samples
derived from healthy subjects and individuals with HIV infection
were determined by ELISA using assay kits from eBioscience.
Statistical Analysis
Statistical analysis of the data was carried out using Prism and
StatviewH and the statistical significance was determined using an
unpaired t-test. Differences were considered significant at a level of
P ,0.05.
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